+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Overactive Bladder Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 4841112
  • Report
  • Region: Global
  • 100 pages
  • Infinium Global Research
UP TO OFF
until Dec 31st 2019
1 of 3

FEATURED COMPANIES

  • Allergan plc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Endo International plc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • MORE
The report on the global overactive bladder treatment market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global overactive bladder treatment market to grow with a CAGR of 3.1% over the forecast period from 2019-2025. The study on overactive bladder treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on overactive bladder treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global overactive bladder treatment market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global overactive bladder treatment market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers
  • Growing the occurrence of overactive bladder (OAB) and increasing prevalence’s of chronic kidney disease (CKD)
  • Growing development of innovative intravesical therapies
2) Restraints
  • Low awareness about overactive bladder treatment among developing countries
3) Opportunities
  • Increasing research for the development of novel drugs
Research Methodology

A) Primary Research
Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders associated with Author
2. Internal and External subject matter experts
3. Professionals and participants from the industry

Our primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global overactive bladder treatment market is segmented on the basis of therapy type, and disease type.

The Global Overactive Bladder Treatment Market by Therapy Type
  • Anticholinergic
  • Solifenacin
  • Fesoterodine
  • Oxybutynin
  • Mirabegron
  • Darifenacin
  • BOTO
  • Neurostimulation
The Global Overactive Bladder Treatment Market by Disease Type
  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity
Company Profiles
The companies covered in the report include
  • Medtronic plc
  • Apotex Inc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • Aurobindo Pharma Limited
  • Sanofi S.A.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo International plc.
  • Mylan N.V.
  • Allergan plc.
  • Other companies
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the overactive bladder treatment market.
2. Complete coverage of all the segments in the overactive bladder treatment market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global overactive bladder treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan plc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Endo International plc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Overactive Bladder Treatment Market Highlights
2.2. Overactive Bladder Treatment Market Projection
2.3. Overactive Bladder Treatment Market Regional Highlights

3. Global Overactive Bladder Treatment Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Therapy Type
3.4.2. Growth Matrix Analysis by Disease Type
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Overactive Bladder Treatment Market

4. Overactive Bladder Treatment Market Macro Indicator Analysis

5. Global Overactive Bladder Treatment Market by Therapy Type
5.1. Anticholinergic
5.2. Solifenacin
5.3. Fesoterodine
5.4. Oxybutynin
5.5. Mirabegron
5.6. Darifenacin
5.7. BOTO
5.8. Neurostimulation

6. Global Overactive Bladder Treatment Market by Disease Type
6.1. Idiopathic Bladder Overactivity
6.2. Neurogenic Bladder Overactivity

7. Global Overactive Bladder Treatment Market by Region 2019-2025
7.1. North America
7.1.1. North America Overactive Bladder Treatment Market by Therapy Type
7.1.2. North America Overactive Bladder Treatment Market by Disease Type
7.1.3. North America Overactive Bladder Treatment Market by Country
7.2. Europe
7.2.1. Europe Overactive Bladder Treatment Market by Therapy Type
7.2.2. Europe Overactive Bladder Treatment Market by Disease Type
7.2.3. Europe Overactive Bladder Treatment Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Overactive Bladder Treatment Market by Therapy Type
7.3.2. Asia-Pacific Overactive Bladder Treatment Market by Disease Type
7.3.3. Asia-Pacific Overactive Bladder Treatment Market by Country
7.4. RoW
7.4.1. RoW Overactive Bladder Treatment Market by Therapy Type
7.4.2. RoW Overactive Bladder Treatment Market by Disease Type
7.4.3. RoW Overactive Bladder Treatment Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Overactive Bladder Treatment Market
8.2. Companies Profiles
8.2.1. Medtronic plc
8.2.2. Apotex Inc.
8.2.3. Intas Biopharmaceuticals
8.2.4. Johnson & Johnson
8.2.5. Aurobindo Pharma Limited
8.2.6. Sanofi S.A.
8.2.7. Hisamitsu Pharmaceutical Co., Inc.
8.2.8. Endo International plc.
8.2.9. Mylan N.V.
8.2.10. Allergan plc.
8.2.11. Other Companies

9. Appendix
9.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Medtronic plc
  • Apotex Inc.
  • Intas Biopharmaceuticals
  • Johnson & Johnson
  • Aurobindo Pharma Limited
  • Sanofi S.A.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Endo International plc.
  • Mylan N.V.
  • Allergan plc.
Note: Product cover images may vary from those shown
Adroll
adroll